<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04904237</url>
  </required_header>
  <id_info>
    <org_study_id>RJH-rAML-2021</org_study_id>
    <nct_id>NCT04904237</nct_id>
  </id_info>
  <brief_title>Aza-Ven Followed by Reduced Toxicity Conditioning Regimen (MBF) as Salvage Therapy for Refractory AML.</brief_title>
  <official_title>Azacytidine-venetoclax Combination as Leukemia Debulking Treatment Followed by Reduced Toxicity Conditioning Regimen (Melphalan Busulfan and Fludarabine, MBF) as Salvage Therapy for Refractory Acute Myeloid Leukemia (AML).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this phase clinical trail, we evaluate the efficacy and feasibility of azacytidine and&#xD;
      venetoclax as leukemia debulking treatment followed by reduced intensity conditioning regimen&#xD;
      consisting of Fludarabine + Busulfan + Melphalan as salvage treatment in patients with&#xD;
      refractory AML .&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In refractory AML, allogeneic hematopoietic stem cell transplantation (allo-HCST) is&#xD;
      considered as the only curative regimen. In this phase II clinical trial, we plan to evaluate&#xD;
      the efficacy and feasibility of new sequential transplantation protocol. All patients receive&#xD;
      azacytidine and venetoclax as leukemia debulking treatment which is followed by reduced&#xD;
      intensity conditioning regimen consisting of Fludarabine (150mg/m2) + Busulfan (6.4mg/kg) +&#xD;
      Melphalan (70mg/m2). The graft-versus host disease (GVHD) prophylaxis regimen is based on&#xD;
      reduced dose of post-transplantation cyclophosphamide (PT-CY) 40mg/kg day+3~+4, tacrolimus&#xD;
      and low-dose anti-thymoglobulin (ATG, 2.5mg/kg) in case of HLA-matched unrelated donor or&#xD;
      halo-donor transplantation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>relapse-free survival</measure>
    <time_frame>12 months</time_frame>
    <description>event defined as relapse or death of any causes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>12 months</time_frame>
    <description>event defined as death of all causes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>non-relapse mortality</measure>
    <time_frame>12 months</time_frame>
    <description>event defined as death of all causes other than leukemia relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>relapse</measure>
    <time_frame>12 months</time_frame>
    <description>event defined as leukemia relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GVHD and relapse free survival (GRFS)</measure>
    <time_frame>12 months</time_frame>
    <description>event defined as leukemia relapse, death of any causes, III-IV aGVHD or moderate to severe cGVHD</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">23</enrollment>
  <condition>Refractory Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>aza-ven +MBF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>treatment with aza-ven debulking therapy followed by allo-HSCT with MBF conditioning</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aza-Ven-allo-HSCT</intervention_name>
    <description>aaa-ven treatment followed by allo-HCTS with reduced toxicity conditioning (RTC) of Fludarabine, Busulifan and Melphalan</description>
    <arm_group_label>aza-ven +MBF</arm_group_label>
    <other_name>Aza-Ven MBF</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  refractory AML (no remission after 2 induction therapy, relapsed AML within 6 months&#xD;
             of first complete remission (CR), relapse AML no CR after reinduction therapy),&#xD;
             multiple relapse and refractory relapse AML&#xD;
&#xD;
          -  patients with HLA matched related or unrelated donor (9~10/10) or haplo-identical&#xD;
             related donor&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with poor liver function (enzyme &gt;2N or bilirubin &gt;2N)&#xD;
&#xD;
          -  poor renal function (Scr &gt;1.5N)&#xD;
&#xD;
          -  poor cardiac function （EF&lt;45%）&#xD;
&#xD;
          -  inform consent not provided&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jiong HU</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Rui Jin Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jiong HU</last_name>
    <phone>86-21-64370045</phone>
    <phone_ext>601878</phone_ext>
    <email>hj10709@rjh.com.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jie-ling Jiang</last_name>
    <phone>86-21-64370045</phone>
    <phone_ext>601878</phone_ext>
    <email>jiangjieling66@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Blood &amp; Marrow Transplantation Center, RuiJin Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiong HU, M.D.</last_name>
      <phone>86-21-64370045</phone>
      <phone_ext>601818</phone_ext>
      <email>hj10709@rjh.com.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Hematology, Shanghai No6 Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chunkang Chang</last_name>
      <phone>86-21-64369181</phone>
      <email>changchunkang@sjtu.edu.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai ZhaXin Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chun Wang</last_name>
      <phone>13386259777</phone>
      <email>wangchun2@medmail.com.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 22, 2021</study_first_submitted>
  <study_first_submitted_qc>May 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 27, 2021</study_first_posted>
  <last_update_submitted>May 27, 2021</last_update_submitted>
  <last_update_submitted_qc>May 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Jiao Tong University School of Medicine</investigator_affiliation>
    <investigator_full_name>Jiong HU</investigator_full_name>
    <investigator_title>Head BMT program, Rui Jin Hospital</investigator_title>
  </responsible_party>
  <keyword>refractory</keyword>
  <keyword>acute myeloid leukemia</keyword>
  <keyword>hematopoietic stem cell transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

